In sum, the polyphenol HT combined with the anti-EGFR antibody cetuximab, produces a robust inhibition of colon cancer cell growth, a remarkable effect that occurs at concentrations of each agent representing a fraction (approx. 1/10) of that producing near maximal effect as single molecules. The gene discussed is EGFR; the disease is colonic neoplasm.